<DOC>
	<DOCNO>NCT00267202</DOCNO>
	<brief_summary>This study design investigate use omalizumab pretreatment patient persistent allergic asthma candidate allergen immunotherapy ( ie , allergy shot ) test hypothesis omalizumab may reduce rate systemic reaction immunotherapy patient persistent allergic asthma .</brief_summary>
	<brief_title>Study Evaluate Effect Omalizumab Improving Tolerability Specific Immunotherapy Patients With Persistent Allergic Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Patients eligible inclusion meet follow criterion : Informed Consent Patients inform study procedure medication provide write informed consent Demographics Male female Any race Ages 18 55 year Body weight &gt; =20 kg &lt; =150 kg Total serum IgE concentration &gt; =30 &lt; =700 IU/mL Visit 0 Disease Definitions/Medications History least moderate persistent allergic asthma ( consistent Global Initiative Asthma [ GINA ] guideline &gt; =1 year duration On stable asthma treatment regimen include inhaled corticosteroid precede 4 week An FEV1 withholding shortacting betaagonists least 6 hour longacting betaagonists least 12 hour , &gt; =75 % predict value Visit 0 Evidence reversible airway obstruction , define increase FEV1 &gt; =12 % 20 30 minute 4 puff ( less discretion investigator ) inhale shortacting betaagonist administration Visit 0 within precede year Documented sensitivity perennial aeroallergens , evidence positive skin test ( wheal &gt; =5mm great saline control ) least 1 3 perennial aeroallergens ( house dust mite , cat , dog ) Visit 0 within precede year Average PEFR variability &lt; =20 % ( calculate [ ( PM PEF AM PEF ) / ( PM PEF + AM PEF ) /2 x 100 ) 2week screen period Prespecified level nocturnal asthma symptom ( i.e. , mean nocturnal asthma score &gt; 0 &lt; =0.5 ) mean combine clinical symptom score ( nocturnal , morning , daytime ) &gt; 0 &lt; =3 screen period Nonsmoker least 1 year prior Visit 1 , smoke history 10 packyears ( i.e. , 1 pack [ 20 cigarette ] per day 10 year ) Judged good physical mental health ( except his/her asthma ) , base medical history , physical examination , routine laboratory data , appear able successfully complete trial Patients exclude participation meet follow criterion : Pulmonary History intubation asthma Asthma exacerbation require treatment systemic steroid within precede 3 month Asthma exacerbation require treatment emergency department hospital admission precede 6 month Upper respiratory tract infection sinusitis within precede 4 week History anaphylactic allergic reaction ( except sting insect , food , drug omalizumab ) History treatment immunotherapy allergen within past 3 year History aspirin non steroidal antiinflammatory drug ( NSAID ) relate asthma ; patient could include NSAIDs use avoid duration study General Medical History current malignancy Any clinically significant uncontrolled systemic disease history disease ( e.g. , infectious , hematologic , renal , hepatic , endocrinologic , gastrointestinal , cardiovascular disease ) within previous 3 month Clinically significant laboratory abnormality Visit 1 Platelet level &lt; =130 x 10 9/L visit 1 Women childbearing potential practicing medically approve contraception method ( e.g. , oral , subcutaneous , mechanical , surgical contraception ) , well woman pregnant nursing History hypersensitivity ingredient , include excipients ( sucrose , histidine , polysorbate 20 ) study medication drug relate omalizumab ( e.g. , monoclonal antibody polyclonal gammaglobulin ) Severe medical condition ( ) , view investigator , prohibit participation study Previous treatment omalizumab within 1 year screening Considered investigator potentially unreliable may reliably attend study visit History drug alcohol abuse Procedural Unable perform acceptable , reproducible spirometry , PEFR measurements Unable unwilling comply study procedure determine screen phase , include adequate completion diary Medications Patient take follow medication Visit 0 . These medication permit trial unless otherwise specify : Oral , intravenous , intramuscular , intraarticular corticosteroid within 4 week Betaadrenergic antagonist ( include ocular preparation ) within 1 week Antihistamines within 1 week ; skin test complete ( Visit 0 ) , antihistamine could use need remainder study Intravenous gammaglobulin immunosuppressant within 4 week Tricyclic antidepressant within 1 week Investigational drug within 4 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Allergic Asthma , IgE , immunotherapy , omalizumab</keyword>
</DOC>